<DOC>
	<DOCNO>NCT00606866</DOCNO>
	<brief_summary>The purpose study determine maximum tumor shrinkage , time progression , survival , drug concentration , degree skin toxicity .</brief_summary>
	<brief_title>MRI Study BAY 43-9006 Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm metastatic clear cell renal cell cancer ; At least one lesion accurately measure least one dimension ; Patients must treat prior antitimor kinase inhibitor VEGF pathway inhibitor ; Age 18 older ; ECOG performance status 02 ; Blood pressure high 140/90 2 separate occasion 6 week prior enrollment less 24 hour apart ; Normal organ function : total bilirubin less upper limit normal , AST le 2.5 X upper limit normal , creatinine less 2.8 mg/dl ; Women childbearing potential men must agree use adequate contraception prior study entry duration study participation ; Ability understand willingness sign write informed consent document . Chemotherapy radiotherapy within 4 week prior enter study ; Any investigational agent ; Known brain metastasis ; Uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>renal , metastatic , carcinoma</keyword>
</DOC>